Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.
about
Extended-spectrum beta-lactamases: a clinical updateOptimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.Extended-spectrum beta-lactamases and clinical outcomes: current data.Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella speciesDiagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms.In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.The continuing challenge of ESBLs.Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.Cefepime: a reappraisal in an era of increasing antimicrobial resistance.The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.Clinical significance of extended-spectrum beta-lactamases.Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis.Impact of sample size on the performance of multiple-model pharmacokinetic simulations.Does Antibiotic Resistance Evolve in Hospitals?Extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae: critical tools for antibiotic resistance pattern.Use of β-Lactam/β-Lactamase Inhibitors for Extended-Spectrum-β-Lactamase Infections: Defining the Right Patient Population.Activity of cefquinome against extended-spectrum β-lactamase-producing Klebsiella pneumoniae in neutropenic mouse thigh model.Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae.Efficacy and Pharmacokinetics of the Combination of OP0595 and Cefepime in a Mouse Model of Pneumonia Caused by Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniae.Efficacy of two-time prophylactic intravenous administration of tazobactam/piperacillin for transrectal ultrasound-guided needle biopsy of the prostate.Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae.Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to cephalosporins and aztreonam by the revised CLSI breakpoints.Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.The efficacy of intravitreal piperacillin/tazobactam in rabbits with experimental Staphylococcus epidermidis endophthalmitis: a comparison with vancomycin.Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.Point-Counterpoint: Piperacillin-tazobactam should be used to treat infections with ESBL-positive organisms.The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections.Investigation on outcomes and bacterial distributions of liver cirrhosis patients with gram-negative bacterial bloodstream infection.Antibacterial effect evaluation of moxalactam against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae with in vitro pharmacokinetics/pharmacodynamics simulation.β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems.Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.
P2860
Q24534999-A1E9CB18-DCB7-465E-8B7F-0AFDD2DED655Q30939930-527928C2-60AF-4EE7-BADA-8D042311084FQ33236875-CA60C9C2-58A8-4243-8AE7-AE77D894F8D4Q34077003-90326D57-26DF-4B16-8EB7-353651CA798AQ34680546-FE761B1B-8C0A-48F5-8996-7C3E95986E08Q35356144-2162FA47-239B-4711-8B65-1B2436DB6A2FQ35666617-5636DCB9-47A5-42A9-84BB-737A1F806D34Q36083619-60F88C95-3228-4D7B-BC25-DB91E70C4431Q36364174-10E7CAC4-A955-4DA7-A181-C89F70FAA866Q36449603-1A9571C8-A22F-40C6-8918-7D713A9AA3D2Q36839703-2CA3F3DF-CBCA-4BE8-97CF-33BEB60BAABBQ37079350-C6D47B7C-FA6C-42EC-97A6-4AA3C53DDA7FQ37098999-0E507A8B-6506-4CD9-85A6-C3C06D7D9592Q37291354-8F444902-B9A6-4FDE-B75C-3E2613985AD7Q37625193-83AEBA4F-7C4A-4600-815F-8B4AE02B832AQ38165138-6DBAF240-0D0A-42BE-87AA-ECB11AFCB734Q38401630-ADABBA9E-78C9-4A6A-AA74-550C7F6838CFQ38681779-A970FD9D-9167-4F85-9F30-1AF1F30EB0CDQ39078075-64B2E61B-362E-4393-86CC-B89442F9D165Q39125398-C9CCA76F-D08D-4308-85E6-6BD28BBB7061Q39233531-D01A7E5A-7B3E-4E37-964B-2E99753CB356Q39353134-FC9B744E-759C-4A11-BE6B-D764C2C24E74Q39451172-F392FF98-AEE9-4F62-861B-8EFB1FB88C4AQ40044307-913AB598-72D7-492B-8F83-206B6B8E4CFDQ40211709-5AAE21A5-58A9-44F0-BD36-89A13748E22EQ40949368-824AE2B6-2291-49E1-9FFB-E0C040718B22Q41004466-0B8E872F-AB5D-480E-9172-C57989289971Q41779878-31C0815D-1064-4059-A51A-9C847C5DD18CQ45341557-C9F0C37C-2F42-46DE-B80E-8A17AFB4EE1AQ46533701-3C5FC8AF-D00B-4DC2-9DA2-DB2B69B5D30CQ46592051-D538D89B-A932-4088-B949-8867CD16FFC5Q46738447-4F038241-CE16-47E5-8411-332851D8BD63Q47315442-88AC91C0-17FA-4B42-97D5-8769BDDF0842Q47427370-507DA56F-4277-416F-89D9-4BE199A6CCD5Q49171086-211795A6-B930-4E3E-BEF5-D24892E580BBQ49376241-9706D9B6-FC98-4AC7-9F42-97B6CA82B253Q50523195-8E0F3B1F-418D-4057-BD99-0ECCE63346E2Q52695014-18584844-DB23-47E7-8C03-D33AA2C248DBQ53693902-13F58F35-A198-491C-B051-91A957857566Q54333207-8DB5730E-8D86-47BF-862D-482ADF664800
P2860
Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pharmacokinetics-pharmacodynam ...... eport from the ARREST program.
@ast
Pharmacokinetics-pharmacodynam ...... eport from the ARREST program.
@en
Pharmacokinetics-pharmacodynam ...... eport from the ARREST program.
@nl
type
label
Pharmacokinetics-pharmacodynam ...... eport from the ARREST program.
@ast
Pharmacokinetics-pharmacodynam ...... eport from the ARREST program.
@en
Pharmacokinetics-pharmacodynam ...... eport from the ARREST program.
@nl
prefLabel
Pharmacokinetics-pharmacodynam ...... eport from the ARREST program.
@ast
Pharmacokinetics-pharmacodynam ...... eport from the ARREST program.
@en
Pharmacokinetics-pharmacodynam ...... eport from the ARREST program.
@nl
P2093
P2860
P1476
Pharmacokinetics-pharmacodynam ...... eport from the ARREST program.
@en
P2093
P G Ambrose
S M Bhavnani
P2860
P304
P356
10.1128/AAC.47.5.1643-1646.2003
P407
P577
2003-05-01T00:00:00Z